SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 2/14/20 Unitedhealth Group Inc 10-K 12/31/19 112:20M |
Document/Exhibit Description Pages Size 1: 10-K Annual Report HTML 2.43M 2: EX-4.5 Instrument Defining the Rights of Security Holders HTML 34K 3: EX-10.17 Material Contract HTML 217K 4: EX-10.18 Material Contract HTML 38K 5: EX-10.44 Material Contract HTML 73K 6: EX-10.45 Material Contract HTML 36K 7: EX-10.46 Material Contract HTML 37K 8: EX-21.1 Subsidiaries List HTML 298K 9: EX-23.1 Consent of Experts or Counsel HTML 32K 10: EX-24.1 Power of Attorney HTML 39K 11: EX-31.1 Certification -- §302 - SOA'02 HTML 46K 12: EX-32.1 Certification -- §906 - SOA'02 HTML 35K 22: R1 Cover Document HTML 96K 79: R2 Consolidated Balance Sheets HTML 133K 89: R3 Consolidated Balance Sheet (Parenthetical) HTML 58K 59: R4 Consolidated Statements of Operations HTML 107K 23: R5 Consolidated Statements of Comprehensive Income HTML 76K 80: R6 Consolidated Statements of Changes in Equity HTML 109K 90: R7 Consolidated Statement of Changes in Equity HTML 33K (Parentheticals) 58: R8 Consolidated Statements of Cash Flows HTML 132K 24: R9 Description of Business (Notes) HTML 32K 108: R10 Basis of Presentation, Uses of Estimates and HTML 96K Significant Accounting Policies (Notes) 75: R11 Investments (Notes) HTML 213K 40: R12 Fair Value (Notes) HTML 151K 53: R13 Property, Plant, and Capitalized Software (Notes) HTML 54K 109: R14 Goodwill and Intangible Assets (Notes) HTML 115K 76: R15 Medical Costs Payable (Notes) HTML 81K 41: R16 Commercial Paper and Long-Term Debt (Notes) HTML 260K 54: R17 Income Taxes (Notes) HTML 163K 110: R18 Shareholders' Equity (Notes) HTML 51K 74: R19 Share-Based Compensation (Notes) HTML 110K 19: R20 Commitments and Contingencies (Notes) HTML 54K 55: R21 Business Combinations Business Combinations HTML 44K (Notes) 92: R22 Segment Financial Information (Notes) HTML 308K 81: R23 Quarterly Financial Data (Unaudited) (Notes) HTML 82K 20: R24 Schedule I (Notes) HTML 202K 56: R25 Basis of Presentation, Uses of Estimates and HTML 153K Significant Accounting Policies (Policies) 93: R26 Fair Value Fair Value (Policies) HTML 44K 82: R27 Schedule I (Policies) HTML 122K 18: R28 Basis of Presentation, Uses of Estimates and HTML 71K Significant Accounting Policies (Tables) 57: R29 Investments (Tables) HTML 209K 52: R30 Fair Value (Tables) HTML 143K 38: R31 Property, Plant, and Capitalized Software (Tables) HTML 52K 78: R32 Goodwill and Intangible Assets (Tables) HTML 122K 112: R33 Medical Costs Payable (Tables) HTML 83K 51: R34 Commercial Paper and Long-Term Debt (Tables) HTML 262K 37: R35 Income Taxes (Tables) HTML 165K 77: R36 Shareholders' Equity (Tables) HTML 49K 111: R37 Share-Based Compensation (Tables) HTML 115K 49: R38 Commitments and Contingencies (Tables) HTML 45K 39: R39 Business Combinations Business Combinations HTML 41K (Tables) 65: R40 Segment Financial Information (Tables) HTML 300K 28: R41 Quarterly Financial Data (Unaudited) (Tables) HTML 82K 85: R42 Schedule I (Tables) HTML 208K 95: R43 Basis of Presentation, Uses of Estimates and HTML 96K Significant Accounting Policies (Details) 63: R44 Basis of Presentation, Uses of Estimates and HTML 43K Significant Accounting Policies Useful lives for property, equipment and capitalized software (Details) 27: R45 Basis of Presentation, Uses of Estimates and HTML 56K Significant Accounting Policies Redeemable Noncontrolling Interests (Details) 84: R46 Investments (Narrative) (Details) HTML 42K 94: R47 Investments (Short-Term and Long-Term Investments) HTML 82K (Details) 62: R48 Investments (Amortized Cost and Fair Value of HTML 104K Available-for-Sale Debt Securities by Contractual Maturity) (Details) 29: R49 Investments (Fair Value of Available-For-Sale HTML 67K Investments with Gross Unrealized Losses by Investment Type and Length of Time That Individual Securities Have Been in a Continuous Unrealized Loss Position) (Details) 35: R50 Fair Value (Narrative) (Details) HTML 39K 46: R51 Fair Value (Financial Assets and Liabilities, HTML 88K Measured at Fair Value on a Recurring Basis) (Details) 100: R52 Fair Value (Financial Assets and Liabilities, Not HTML 56K Measured at Fair Value on a Recurring Basis) (Details) 66: R53 Property, Plant, and Capitalized Software HTML 36K (Narrative) (Details) 36: R54 Property, Plant, and Capitalized Software Property HTML 56K Plant and Equipment Table (Details) 47: R55 Goodwill and Intangible Assets (Narrative) HTML 34K (Details) 101: R56 Goodwill and Intangible Assets Changes in the HTML 51K Carrying Amount of Goodwill by Reporting Segment (Details) 67: R57 Goodwill and Intangible Assets Gross carrying HTML 49K value, accumulated amortization and net carrying value of intangible assets (Details) 34: R58 Goodwill and Intangible Assets Weighted-average HTML 43K useful lives assigned to finite-lived intangible assets acquired in business combinations (Details) 48: R59 Goodwill and Intangible Assets Amortization HTML 43K Expense relating to Intangible Assets (Details) 96: R60 Medical Costs Payable (Narrative) (Details) HTML 31K 87: R61 Medical Costs Payable Rollforward (Details) HTML 55K 25: R62 Medical Costs Payable, Incurred and Paid Medical HTML 46K Cost Development (Details) 60: R63 Commercial Paper and Long-Term Debt (Narrative) HTML 61K (Details) 98: R64 Commercial Paper and Long-Term Debt (Details) HTML 210K 88: R65 Commercial Paper and Long-Term Debt Maturities of HTML 48K commercial paper and long-term debt (Details) 26: R66 Income Taxes (Narrative) (Details) HTML 65K 61: R67 Income Taxes Reconciliation of Provision for HTML 49K Income Taxes (Details) 99: R68 Income Tax Reconciliation of the tax provision at HTML 86K the U.S. Federal Statutory Rate (Details) 86: R69 Income Taxes Components of Deferred Tax Assets and HTML 90K Liabilities (Details) 71: R70 Income Taxes Reconciliation of the beginning and HTML 46K ending amount of unrecognized tax benefits (Details) 107: R71 Shareholders' Equity (Narrative) (Details) HTML 43K 45: R72 Shareholders' Equity Share Repurchases (Details) HTML 42K 33: R73 Share-Based Compensation (Narrative) (Details) HTML 38K 68: R74 Share-Based Compensation (Stock Option Activity) HTML 80K (Details) 104: R75 Share-Based Compensation (Restricted Share HTML 48K Activity) (Details) 42: R76 Share-Based Compensation Other Share-Based HTML 63K Compensation Data (Details) 30: R77 Share-Based Compensation (Share-Based Compensation HTML 58K Principal Fair Value Assumptions) (Details) 73: R78 Commitments and Contingencies (Narrative) HTML 47K (Details) 103: R79 Commitments and Contingencies Future Lease HTML 55K Payments (Details) 70: R80 Business Combinations Acquired Assets and HTML 49K Liabilities (Details) 106: R81 Business Combinations Business Combinations HTML 39K (Details) 44: R82 Segment Financial Information (Narrative) HTML 45K (Details) 32: R83 Segment Financial Information (Details) HTML 125K 69: R84 Quarterly Financial Data (Unaudited) (Details) HTML 70K 105: R85 Schedule I (Details) HTML 43K 43: R86 Schedule I Condensed Balance Sheets (Details) HTML 113K 31: R87 Schedule I Balance Sheet Document (Details) HTML 52K 72: R88 Schedule I Condensed Statement of Comprehensive HTML 73K Income (Details) 102: R89 Schedule I Statement of Cash Flows (Details) HTML 109K 97: R90 Schedule I Maturities of Commercial Paper and HTML 52K Long-Term Debt (Details) 50: XML IDEA XML File -- Filing Summary XML 203K 64: XML XBRL Instance -- unh2019123110-k_htm XML 5.37M 83: EXCEL IDEA Workbook of Financial Reports XLSX 133K 14: EX-101.CAL XBRL Calculations -- unh-20191231_cal XML 310K 15: EX-101.DEF XBRL Definitions -- unh-20191231_def XML 1.42M 16: EX-101.LAB XBRL Labels -- unh-20191231_lab XML 2.46M 17: EX-101.PRE XBRL Presentations -- unh-20191231_pre XML 1.68M 13: EX-101.SCH XBRL Schema -- unh-20191231 XSD 232K 91: JSON XBRL Instance as JSON Data -- MetaLinks 515± 798K 21: ZIP XBRL Zipped Folder -- 0000731766-20-000006-xbrl Zip 654K
Exhibit |
1. | I have reviewed this report on Form 10-K of UnitedHealth Group Incorporated
(the “registrant”); |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows
of the registrant as of, and for, the periods presented in this report; |
4. | The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a) | Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c) | Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d) | Disclosed in this report any change
in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
5. | The
registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process,
summarize and report financial information; and |
b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
Chief Executive Officer | |
1. | I have reviewed this report on Form 10-K of UnitedHealth Group Incorporated (the “registrant”); |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
registrant and have: |
a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b) | Designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c) | Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d) | Disclosed
in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
5. | The
registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process,
summarize and report financial information; and |
b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
/s/ JOHN
F. REX | |
John F. Rex Executive Vice President and Chief Financial Officer |
This ‘10-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 2/14/20 | SC 13G | ||
For Period end: | 12/31/19 | 11-K | ||
List all Filings |